Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
from the 10Q 3/2020
Anti-dilutive common share equivalents excluded from the computation of diluted net loss per share at March 31, 2020 consisted of stock options of 25,535,000 and unvested performance stock options of 8,000,000. Anti-dilutive common share equivalents excluded from the computation of diluted net loss per share at March 31, 2019 consisted of stock options of 25,830,000 and unvested performance stock options of 10,750,000.
The fully dilutive share count will go up when the options are in the money
Warren Buffet is a HUGE hypocrite. WB feels People should pay their “fair share” but He donates his stock to his foundations, avoiding massive capital gains. He should sell the shares, pay the tax, and donate the net to his foundations. What he is telling you is that it is OK for the government to spend my tax dollars , but he doesn’t trust the government to spend his tax dollars
Citron Research was long. So happy Andrew Left got burned after all the pain his short tweets have caused.
Remote monitor for COVID-19
https://seekingalpha.com/news/3553671-masimo-debuts-remote-patient-management-system
Will the make a bid for $SPOK? Paging with healthcare vertical
$VRNDF: $.37 See the pre-release of Delta 9, Canadian $32M micro cap. 4Q sales of $10M-$10.5M
about 50% q/q. Produced 1.3M grams with cost of $0.91-$1.04. Back of the envelope looks like a profitable quarter. Reports on 3/19
https://www.globenewswire.com/news-release/2020/03/10/1997868/0/en/Delta-9-Provides-Guidance-Timing-for-Year-End-Results.html
High Gear is now, +10M in revenue for quarter, 1.3M grams produced , and cost of .94-1.04 per gram. See the pre-release
https://www.globenewswire.com/news-release/2020/03/10/1997868/0/en/Delta-9-Provides-Guidance-Timing-for-Year-End-Results.html
$VRNDF - Delta 9 Cannabis, Pre-released Looks like will have operating profit this Q +10M Revenue, 1.3M Grams with cost of $0.91 -$1.04 per gram
https://www.globenewswire.com/news-release/2020/03/10/1997868/0/en/Delta-9-Provides-Guidance-Timing-for-Year-End-Results.html
Vitamin Shop, Yes in stock in North East Ohio, but gold 30 count 15mg $53, vs 30ct 30mg Garden of life full spectrum for $44 (sale). There were many different brands at least 5 by my count and there were probably more I missed. Product data sheet for Garden of Life was detailed, so felt comfortable buying it.
Just some general info, on the competitive marketplace, and my be why reorders have slowed
I'm long CVSI, but will see after the call
$WDDMF, Insurance to pay for Medical Cannabis!!
February 10, 2020 07:00 ET | Source: WeedMD Rx Inc.
TORONTO, Feb. 10, 2020 (GLOBE NEWSWIRE) -- WeedMD Inc. (TSX-V:WMD) (OTCQX:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical-grade cannabis, is pleased to announce that its subsidiary Starseed Medicinal Inc. (“Starseed”) is now the preferred supplier of medical cannabis to over 51,000 eligible myHSA participants across Canada. Selling its platform through a network of over 2,600 advisors, working with over 8,500 employers, myHSA is widely recognized for its unique digital wellness and reimbursement platform that provides a flexible, interactive benefits menu.
“More companies are recognizing that wellness programs are an effective way to engage employees in healthier living and we’re pleased to partner with innovative benefits provider myHSA as it looks to expand access to quality cannabis products to its 51,000 members,” said Angelo Tsebelis, CEO of WeedMD. “With the onset of flexible digital solutions, myHSA’s eligible participants get direct access to our patient portals and full-service medical cannabis program as well as easy digital access to claim reimbursement and adjudication.”
“At myHSA, we strongly believe that employees need to be in control of their wellness journey and with the advent of alternative therapies, we wanted to partner with a trusted source of medical cannabis products to ensure our participants have access to top quality products from Starseed and WeedMD,” said Tim Kane, CEO of myHSA. “We’ve created a platform that empowers participants to choose how they would like to spend their wellness dollars as a way to motivate and inspire a more holistic approach to benefits coverage.”
Launched in 2013, myHSA has grown and is the main spending account provider to over 51,000 employees across Canada. The myHSA system is a software that is used by advisors to implement different forms of health spending accounts, insurance products, and other unique employee benefits
$LXXGF LexaGene Analyzer Designed to Detect Pathogens like Coronavirus
LexaGene’s Analyzer is Designed to Detect Pathogens such as the Novel Coronavirus to Help Avert a Pandemic
BEVERLY, Mass. – January 27, 2020 – LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a biotechnology company that develops genetic analyzers for the rapid detection of pathogens and other molecular markers, has received many inquiries regarding the ability of LexaGene’s technology for detecting coronavirus.
“LexaGene’s technology is ideally suited to identify novel pathogens such as coronavirus. Our genetic analyzer can quickly detect new pathogens in just one hour, on-site. Currently, the traditional process requires that samples from sick individuals must be transported to laboratories for manual processing. This is extremely inefficient and introduces a significant time-delay that can have severe consequences for disease spread. Today’s coronavirus outbreak highlights why LexaGene’s technology is needed so desperately,” said Dr. Jack Regan, LexaGene’s CEO and Founder.
This new pathogen first emerged in mid-December when several workers in the Huanan Seafood Market of Wuhan, China displayed symptoms of severe pneumonia from an unknown pathogen. On January 9th, China CDC reported that the infections were due to a novel coronavirus, currently referred to as 2019-nCoV. In an attempt to control disease spread, the Chinese government has quarantined entire cities, and international airports are now screening travelers from affected areas. Despite these efforts, the World Health Organization reported that by January 26th, over 2,000 cases had been confirmed and 56 deaths were reported.1 Human-to-human transmission has been confirmed and the disease has quickly spread to ten other countries, including the United States, France, Canada, and Australia. The risk of a pandemic is now very real.
Dr. Regan continues, “Developing a new diagnostic test to detect this coronavirus is important and has already been done by numerous groups.2 The challenge is bringing these manually performed tests out of the specialized reference laboratories that can take days to return results and instead to the points-of-need, which are the clinics, hospitals, and airports where answers are needed in one hour or less. Currently, no technology exists that allows for these locations to readily start screening for a new threat within days of an outbreak being identified. LexaGene is addressing this urgent problem and has developed the first ever, easy-to-use, open-access diagnostic analyzer that is designed to help control the spread of deadly outbreaks such as this 2019 coronavirus.”
LexaGene’s microfluidic technology is designed for on-site use and screens for both common pathogens and new bio-threats. This is possible due to its open-access feature that permits non-technical operators to quickly add new tests to detect novel pathogens.
LexaGene is now finalizing the design of its commercial instrument, which it anticipates starting to manufacture in a few months, with the expectation of achieving first commercial sales in Q3 of this year. For implementation in hospitals, clinics, airports, and other locations interested in processing human samples for clinical purposes, the Company will need either Emergency Use Authorization (EUA) or 510(k) clearance from the Food and Drug Administration (FDA).
1 https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200126-sitrep-6-2019–ncov.pdf?sfvrsn=beaeee0c_4
2 https://www.who.int/docs/default-source/coronaviruse/wuhan-virus-assay-v1991527e5122341d99287a1b17c111902.pdf
About LexaGene Holdings Inc.
LexaGene is a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press ‘go’. The LX Analyzer delivers excellent sensitivity, specificity, and breadth of detection and can return results in about 1 hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.
Media Contacts
Nicole Ridgedale
Director of Corporate Marketing, LexaGene
800.215.1824 ext 206
nridgedale@lexagene.com
$LXXGF One hour Superbug Test
Tests Achieve 100% Concordance on Superbugs
Newly-developed Tests Achieve 100% Concordance on Superbug Strains from the CDC
BEVERLY, Mass. – January 21, 2020 – LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today it has expanded its number of validated tests for antibiotic resistance and has completed testing different superbug isolates provided by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) Antibiotic Resistance (AR) Isolate Bank.
Dr. Jack Regan, LexaGene’s CEO and Founder states, “Antibiotic resistance is a big problem. People are dying every day due to the lack of high-quality, rapid diagnostics at the point of care that can both identify the cause of an infection and determine whether it is resistant to common antibiotics. To address this shortcoming, LexaGene has developed a fully automated, molecular-based diagnostic that can provide these answers in an hour – rather than the typical 3-day turnaround time for a sample shipped to a reference laboratory. To evaluate our newly developed assays, we tested them against the most dangerous antibiotic-resistant bugs we could get our hands on and have been thrilled with the data – as we successfully detected 100% of the targeted genetic sequences.”
Antibiotic resistance is one of the biggest public health threats of our time. Currently, more than 2.8 million antibiotic-resistant infections occur in the U.S. each year, and more than 35,000 people die as a result.1 The CDC has predicted that by 2050, 10 million people will die from antibiotic-resistant strains every year – surpassing the number of deaths due to cancer in present times.2
LexaGene’s study was broken into two parts, pathogen identification and antibiotic resistance detection.
For pathogen detection, LexaGene’s tests successfully detected each of the 125 targeted strains of bacteria, specifically: 55 Klebsiella sp., 31 Escherichia coli, 22 Enterobacter sp., 14 Acinetobacter baumannii, 12 Pseudomonas aeruginosa, and 5 Proteus mirabilis.
For the second part of the study, 13 different antibiotic resistance tests were used to successfully detect 90 carbapenemase resistant strains and 123 multi-drug resistant strains (carbapenemase + extended-spectrum beta-lactamases).
Dr. Regan concludes, “We now have tests that will detect bacterial pathogens that carry antimicrobial resistance and are responsible for the most commonly misdiagnosed infections. Our goal is to provide healthcare professionals with an easy to use, on-site technology that quickly informs on identified pathogens and detected antimicrobial resistance so they can improve prescription practices. This would be a significant improvement over the current standard, which is to wait three days for lab-generated test results that indicate whether the correct therapies were prescribed.”
Here is a link to the superbug tests. Hey China need a quick test machine?
https://lexagene.com/release/2020/tests-achieve-100-concordance-on-superbugs/
$DUOT, Makes train inspection stuff. 1/14/2020 reported First CSX install, and CSX even posted on their website. Reduces inspection time from hours to minutes.
https://www.csx.com/index.cfm/about-us/a-new-dimension-in-rail-safety-technology/
They will make money one of these days
Long $DUOT
How Long until SMCI is back in the Indexes?
Loan Default: Be careful out there 12/5/2019 8k:
Item 8.01. Other Events
On March 6, 2019, Foothills Exploration, Inc. (the “Company”), closed on a loan transaction by which the Company issued FirstFire Global Opportunities Fund, LLC (“Lender”) a senior secured convertible promissory note (“Note”) in the principal amount of $705,882, and received proceeds of $600,000 before giving effect to certain transactional costs and legal fees. This loan is secured by the Company’s Green River Basin Assets located in Wyoming. For additional description of this secured loan transaction, please see the Company’s current report on Form 8-K filed with the Commission on March 12, 2019.
Since closing on this transaction, the Company made principal payments to Lender totaling $100,000. Lender asserts that amounts owing to it as of September 1, 2019 are approximately $705,882. Following a notice of default, the parties entered into a forbearance agreement to extend the maturity date of the note into January 2020, which included payments of $352,941.17 to be paid on November 29, 2019, and $427,941.18 to be paid on the maturity date as extended.
The Company was unable timely to comply with the payment terms of the forbearance agreement. The Company and Lender may or may not continue discussions concerning possible extensions of payment terms and amounts, however no assurance can be given that the Company will be able to reach agreement with Lender. In that event, Lender has advised the Company that Lender intends to pursue its available legal remedies, including by not limited to litigation, to recover all amounts asserted to be owed to Lender under the applicable loan documents.
Litigation pursued by Lender against the Company can further erode the financial condition and materially and adversely affect operations of the Company and could result in cross-defaults with other lenders. Management is actively working with all of its debtholders to seek resolution on these matters; however, no assurances can be given that management will be able to reach agreement with any of its lenders. As a further result the foregoing the Company may be compelled to seek protection under appropriate state or federal insolvency laws.
Hemp Harvest Video: from September 2019
I Like the dual cut harvest method, (near end)
Hello Space Lady, I rounded down to 19.5M
and hope I'm low
My guess is 19.5M
Last Q Rev was 16,854 with 15.7% online, Therefore Wholesale was 14,208. Store Count @1q=3308, @2Q=4591, Avg 3950: 14,208/3950= 3.597 3Q Ending store Count 5300 with avg est 4,624. 3.6x4624=16,646. 16,646/.85(whole vs online) = 19.58
New Here, but have been long since before Citrion